P234 Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012

@inproceedings{Looker2015P234GE,
  title={P234 Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012},
  author={Katharine J Looker and Amalia Magaret and Katherine Mary Elizabeth Turner and Peter Vickerman and Sami L. Gottlieb and Lori Marie Newman},
  year={2015}
}
Background/introduction Genital herpes, usually caused by infection with herpes simplex virus type 2 (HSV-2), can cause substantial morbidity in the form of painful genital ulcers in infected adults and adolescents, as well as significant psychosocial morbidity. Neonatal herpes, acquired during delivery from mothers with genital herpes, is rare but often fatal. Additionally, HSV-2 increases susceptibility to, and transmissibility of, HIV. The global burden of HSV-2 was last estimated for 2003… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 114 CITATIONS, ESTIMATED 60% COVERAGE

Oral Sex and HSV-1 Knowledge Among College Freshmen Females

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 7 Highly Influenced Citations

  • Averaged 20 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection.

  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2006
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations.

  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2004
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Genital herpes.

VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003. Available: http://irgenoceacom/ releasedetailcfm?ReleaseID5857313

Genocea website
  • 2014
VIEW 1 EXCERPT